Business Context and Reporting Period
This Form 8-K filing by Molina Healthcare, Inc. reports on events occurring on June 5, 2017, with the report dated June 7, 2017. The filing details an amended employment agreement and compensation adjustments for Joseph W. White, the company's Chief Financial Officer and Interim President and Chief Executive Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on executive compensation arrangements.
Material Changes
- Employment Agreement: Entered into an Amended and Restated Employment Agreement with Joseph W. White, effective May 2, 2017, superseding the 2013 agreement.
- Base Salary: Mr. White's annual base salary as CFO is set at $650,000.
- Interim CEO Compensation: While serving as Interim President and CEO, Mr. White receives an additional special salary of $100,000 per month.
- Bonus Opportunity: The target bonus opportunity for Mr. White's role as CFO was increased from 90% to 100% of his Base Salary.
- Equity Grant: Mr. White was granted 15,008 shares of restricted stock, vesting in one-third increments over three years.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or general risk factors. Specific contingencies regarding Mr. White's employment include:
- Severance: In the event of termination without "Cause" or resignation for "Good Reason" (outside of a Change in Control window), Mr. White is entitled to one year of Base Salary, a pro-rata portion of the current year's salary, $50,000 for health benefits, and immediate vesting of time-based restricted shares.
- Change in Control: Different severance terms apply if termination occurs within 12 months of a Change in Control Event.
- Nonsolicitation: Mr. White is restricted from soliciting employees or customers for 12 months post-employment.
Investor Verification Checklist
- Verify the total annualized compensation cost for Mr. White, including the $650,000 base salary, the $1.2 million annualized interim CEO stipend, and the potential 100% bonus.
- Review the full text of Exhibit 10.1 to understand the specific definitions of "Cause" and "Good Reason" which trigger severance.
- Assess the impact of the 15,008 restricted stock grant on dilution and future equity compensation expenses.
- Monitor the timeline for the appointment of a permanent President and CEO, as the interim stipend ceases upon that event.